A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)
Petr Krivorotko(Institute of Oncology NN Petrov), Alexey Manikhas(Centrum Onkologii), Juan Pablo Zarate(Novartis (United States)), Magdalena Wieczorek-Rutkowska(Centrum Onkologii), Tomasz Sarosiek, М. В. Шомова, Stephen Chan(Heidelberg University), Bogusława Karaszewska(State University of Applied Sciences in Konin), Chaitali Babanrao Pisal(Novartis (India)), Lane F. Smith(Novartis (United States)), Е. Г. Овчинникова(Nizhny Novgorod Regional Clinical Oncology Center)
Cited by 0
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
|New England Journal of Medicine|2019|1.4k
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639